<DOC>
	<DOCNO>NCT00688116</DOCNO>
	<brief_summary>An open-label dose escalation study patient solid tumor treat STA-9090 ( ganetespib )</brief_summary>
	<brief_title>Study STA-9090 , Administered Twice-Weekly Patients With Solid Tumors</brief_title>
	<detailed_description>This open-label Phase 1 dose-escalation study patient solid tumor treat STA-9090 ( ganetespib ) evaluate safety , tolerance efficacy .</detailed_description>
	<criteria>Patients must document refractory candidate current approve therapy . Must anECOG status 02 . Peripheral neuropathy ? 2 . Must acceptable organ marrow function per protocol parameter . No clinically significant ventricular arrythmias ischemia . Must pregnant breastfeeding . No chemotherapy radiation within 3 weeks.. No previous radiation &gt; 25 % total bone marrow . No previous high dose chemotherapy autologous allogeniec hematopoietic stem cell transplantation . No primary brain tumor active brain metastasis . No use investigational agent within 4 week . No treatment chronic immunosuppressant . No uncontrolled , intercurrent illness .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>histologically cytologically confirm non-hematological malignancy metastatic unresectable</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
</DOC>